False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17α-hydroxyprogesterone (17-OHP) values

Steroids

Volumn 74, Issue 8, 2009, Pages 662-665

  Fingerhut, Ralph ^a  

^a Laboratory Becker   (Germany)

Author keywords

17 Hydroxyprogesterone; Congenital adrenal hyperplasia; Ether extraction; Newborn screening

Indexed keywords

ETHER; HYDROXYPROGESTERONE;

ARTICLE; BIRTH WEIGHT; BLOOD SAMPLING; CONGENITAL ADRENAL HYPERPLASIA; DIAGNOSTIC ACCURACY; FALSE POSITIVE RESULT; GENETIC ANALYSIS; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN SCREENING; PROGESTERONE BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SOLVENT EXTRACTION; TANDEM MASS SPECTROMETRY;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL HYPERPLASIA, CONGENITAL; ETHER, ETHYL; FALSE POSITIVE REACTIONS; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; SENSITIVITY AND SPECIFICITY;

EID: 67349124987     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2009.02.008     Document Type: Article

References (20)

1. New M.I. Diagnosis and management of congenital adrenal hyperplasia. Annu Rev Med 49 (1998) 311-328
2. Newfield R.S., and New M.I. 21-Hydroxylase deficiency. Ann NY Acad Sci 816 (1997) 219-229
3. Mornet E., Crete P., Kuttenn F., Raux-Demay M.C., Boué J., White P.C., et al. Distribution of deletions and seven point mutations on CYP21B genes in the three clinical forms of steroid 21-hydroxylase deficiency. Am J Hum Genet 48 (1991) 79-88
4. Olgemöller B., Roscher A.A., Liebl B., and Fingerhut R. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab 88 (2003) 5790-5794
5. Speiser P.W., Dupont J., Zhu D., Serrat J., Buegeleisen M., Tusie-Luna M.T., et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 90 (1992) 584-595
6. Therrell Jr. B.L., Berenbaum S.A., Manter-Kapanke V., Simmank J., Korman K., Prentice L., et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 101 (1998) 583-590
7. Schreiner F., Brack C., Salzgeber K., Vorhoff W., Woelfle J., and Gohlke B. False negative 17-hydroxyprogesterone screening in children with classical congenital adrenal hyperplasia. Eur J Pediatr 167 (2008) 479-481
8. Torresani T., Grüters A., Scherz R., Burckhardt J.J., Harras A., and Zachmann M. Improving the efficacy of newborn screening for congenital adrenal hyperplasia by adjusting the cut-off level of 17-hydroxyprogesterone to gestational age. Screening 3 (1994) 77-84
9. Allen D.B., Hoffman G.L., Fitzpatrick P., Laessig R., Maby S., and Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr 130 (1997) 128-133
10. Kösel S., Burggraf S., Fingerhut R., Dörr H.G., Roscher A.A., and Olgemöller B. Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency. Clin Chem 51 (2005) 298-304
11. Lai C.C., Tsai C.H., Tsai F.J., Lee C.C., and Lin W.D. Rapid monitoring assay of congenital adrenal hyperplasia with microbore high-performance liquid chromatography/electrospray ionization tandem mass spectrometry from dried blood spots. Rapid Commun Mass Spectrom 15 (2001) 2145-2151
12. Lacey J.M., Minutti C.Z., Magera M.J., Tauscher A.L., Casetta B., McCann M., et al. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem 50 (2004) 621-625
13. Holtkamp U., Klein J., Sander J., Peter M., Janzen N., Steuerwald U., et al. EDTA in dried blood spots leads to false results in neonatal endocrinologic screening. Clin Chem 54 (2008) 602-605
14. Fingerhut R., Dame T., and Olgemöller B. Determination of EDTA in dried blood samples by tandem mass spectrometry avoids serious errors in newborn screening. Eur J Pediatr 168 (2009) 553-558
15. Wong T., Shackleton C.H.L., Covey T.R., and Ellis G. Identification of the steroids in neonatal plasma that interfere with 17a-hydroxyprogesterone radioimmunoassays. Clin Chem 38 (1992) 1830-1837
16. Shimozawa K., Saisho S., Saito N., Yata J., Igarashi Y., Hikita Y., et al. A neonatal mass-screening for congenital adrenal hyperplasia in Japan. Acta Endocrinol (Copenh) 107 (1984) 513-518
17. Wallace A.M., Beesley J., Thomson M., Giles C.A., Ross A.M., and Taylor N.F. Adrenal status during the first month of life in mature and premature human infants. J Endocrinol 112 (1987) 473-480
18. Hingre R.V., Gross S.J., Hingre K.S., Mayes D.M., and Richman R.A. Adrenal steroidogenesis in very low birth weight preterm infants. J Clin Endocrinol Metab 78 (1994) 266-270
19. Lee M.M., Rajagopalan L., Berg G.J., and Moshang Jr. T. Serum adrenal steroid concentrations in premature infants. J Clin Endocrinol Metab 69 (1989) 1133-1136
20. Ersch J., Beinder E., Stallmach T., Bucher H.U., and Torresani T. 17-Hydroxyprogesterone in premature infants as a marker of intrauterine stress. J Perinat Med 36 (2008) 157-160